RxDoctor Payments DataLook up a doctor →

Jeffrey Rieder, MD

Interventional Cardiology · Charleston, SCNPI 1255397519

Payments from drug & device makers

$17,975in general payments, 2019–2025

Across 680 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$4K
  • Boston Scientific$2K
  • Heartflow, Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Amgen$989
  • Abbott$957
  • plus $8K from 42 others

What the payments were for

  • Consulting fees$4143%
  • Travel & lodging$2872%
  • Food & beverage$13,38595%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,975 in reported general payments places this provider in the 65th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$593,509
Medicare patients
1,729
Services billed
8,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban853$963,566
EntrestoSacubitril/Valsartan124$145,313
MultaqDronedarone Hcl85$129,206
XareltoRivaroxaban122$112,528
JardianceEmpagliflozin67$61,056
Repatha SureclickEvolocumab67$58,086
FarxigaDapagliflozin Propanediol39$36,076
Nebivolol Hcl185$11,027
Praluent PenAlirocumab15$10,686
BrilintaTicagrelor11$8,001
Ranolazine ErRanolazine53$7,951
Rosuvastatin Calcium510$7,807
Ezetimibe181$7,115
Metoprolol Succinate426$6,656
Diltiazem 24hr Er (Cd)Diltiazem Hcl210$6,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$544$963,566853 claims
NovartisEntresto$731$145,313124 claims
Sanofi-aventis U.S. LLCMultaq$239$129,20685 claims
Johnson & JohnsonXarelto$586$112,528122 claims
Boehringer IngelheimJardiance$570$61,05667 claims
AstraZenecaFarxiga, Brilinta$507$44,07750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →